Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment

Not yet recruiting

Phase N/A Results N/A

Summary of Purpose

This study evaluates safety and efficacy of analgesia-first minimal sedation as an early antihypertensive treatment for spontaneous intracerebral hemorrhage. The analgesia-first minimal sedation strategy relies on the remifentanil-mediated alleviation of pain-induced stress response and the antisympathetic activity of dexmedetomidine to restore the elevated blood pressure to normal level in patients with...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 26 February 2018.

1 Mar 2018 26 Jun 2017 1 Feb 2019 1 Aug 2019 1 Feb 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available

Contacts

See All